Century Therapeutics (IPSC) Revenue & Revenue Breakdown
Century Therapeutics Revenue Highlights
Latest Revenue (Y)
$2.23M
Latest Revenue (Q)
$771.00K
Century Therapeutics Revenue by Period
Century Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.23M | -57.01% |
| 2022-12-31 | $5.20M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Century Therapeutics generated $2.23M in revenue during NA 2023, up -57.01% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Century Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $771.00K | -9.82% |
| 2024-03-31 | $855.00K | 219.03% |
| 2023-12-31 | $268.00K | 81.08% |
| 2023-09-30 | $148.00K | 49.49% |
| 2023-06-30 | $99.00K | -94.24% |
| 2023-03-31 | $1.72M | 230.13% |
| 2022-12-31 | $521.00K | -76.57% |
| 2022-09-30 | $2.22M | 59.31% |
| 2022-06-30 | $1.40M | 31.95% |
| 2022-03-31 | $1.06M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Century Therapeutics generated $771.00K in revenue during Q2 2024, up -9.82% compared to the previous quarter, and up 44.83% compared to the same period a year ago.
Century Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| RLAY | Relay Therapeutics | $25.55M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| KZR | Kezar Life Sciences | $7.00M | - |
| GBIO | Generation Bio | $5.90M | $4.06M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| FIXX | Q32 Bio | $1.16M | - |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| NGM | NGM Biopharmaceuticals | - | $165.00K |
| NKTX | Nkarta | - | - |
| ERAS | Erasca | - | - |
| PASG | Passage Bio | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
IPSC Revenue FAQ
What is Century Therapeutics’s yearly revenue?
Century Therapeutics's yearly revenue for 2023 was $2.24M, representing a decrease of -57.01% compared to 2022. The company's yearly revenue for 2022 was $5.2M, representing an increase of 100.00% compared to 2021. IPSC's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Century Therapeutics’s quarterly revenue?
Century Therapeutics's quarterly revenue for Q2 2024 was $771K, a -9.82% decrease from the previous quarter (Q1 2024), and a 678.79% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $855K, a 219.03% increase from the previous quarter (Q4 2023), and a -50.29% decrease year-over-year (Q1 2023). IPSC's quarterly revenue for Q4 2023 was $268K, a 81.08% increase from the previous quarter (Q3 2023), and a -48.56% decrease year-over-year (Q4 2022).
What is Century Therapeutics’s revenue growth rate?
Century Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.